Manufacturers are pressing for greater transparency in the 340B Drug Pricing Program, citing limits in visibility into product distribution paths and exposure across distribution-side and rebate-side mechanics. A key concern is duplicate discounts, where commercial rebates and 340B discounts can both apply, leaving manufacturers with a “black hole” on commercial-side visibility. The push is playing out across litigation and policy discussions involving pharmacy claims data, HRSA’s proposed rebate model, and state-level contract pharmacy access rules. Industry stakeholders argue compliance requires clearer measurement of where 340B product ends up and how it interacts with rebate systems. The development matters for biopharma pricing, contracting, and operational risk—especially as 340B script volumes have expanded with contract pharmacy reach.